CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
856-870 of 1225

Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence

Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence

Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence

Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
- advertisement

Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®Emerging immunotherapy combination strategies in genitourinary malignancies

Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
CME/CE Broadcast ReplayPulmonary Hypertension: Comorbidities With PAH and Group 2 PH

Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
MinuteCE®Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
- advertisement

Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma








































